Equities

ANGN

US03476J1079

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
8.99 ^USD	-1.21%		+7.02%	-10.10%

2023	Angion Biomedica Corp. Announces Resignation of Assaf Segal from Its Board of Directors	CI
2023	Angion Biomedia to Implement 10-for-1 Reverse Split	MT

Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference

January 16, 2024 at 08:31 am EST

BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, and Christopher Haqq, M.D., Ph.D., Executive Vice President, Head of Research and Development, and Chief Medical Officer will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference on January 18, 2024 at 2:30 PM ET.

To access this event, please RSVP to your B. Riley Securities sales representative. A replay of Elicio’s fireside chat will be accessible under “Events” in the Investors section of Elicio’s website, www.elicio.com, after the meeting.

About Elicio Therapeutics
Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer. By combining expertise in immunology and immunotherapy, Elicio is engineering investigational Amphiphile (“AMP”) immunotherapies intended to precisely target and fully engage the lymph nodes, the site in our bodies where the immune response is orchestrated. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants and vaccines for an array of aggressive cancers.

Media Contact
Kristin Politi
LifeSci Communications
kpoliti@lifescicomms.com
646-876-4783

Investor Relations Contact
Heather DiVecchia
Elicio Therapeutics
IR@elicio.com
857-209-0153

Source: Elicio Therapeutics Inc.

2024 GlobeNewswire, Inc., source Press Releases

Latest news about ANGN BIOM

Angion Biomedica Corp. Announces Resignation of Assaf Segal from Its Board of Directors	23-08-30	CI
Angion Biomedia to Implement 10-for-1 Reverse Split	23-06-01	MT
Angion Biomedica Corp.(NasdaqGS:ANGN) dropped from NASDAQ Composite Index	23-06-01	CI
Elicio Therapeutics, Inc. completed the acquisition of Angion Biomedica Corp. from Vifor (International) AG, Eisa-Abc LLC and others in a reverse merger transaction.	23-05-31	CI
Angion Biomedica Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Sector Update: Health Care Stocks Finishing Near Intra-Day Lows	23-01-17	MT
Sector Update: Health Care Stocks Sputtering in Tuesday Trading	23-01-17	MT
Top Midday Decliners	23-01-17	MT
Investors Digest More Big Bank Earnings, Weighing on US Equity Futures	23-01-17	MT
Top Premarket Decliners	23-01-17	MT
Angion Biomedica Agrees to Merge With Elicio Therapeutics	23-01-17	MT
Elicio Therapeutics, Inc. entered into a definitive merger agreement to acquire Angion Biomedica Corp. from Vifor (International) AG, Eisa-Abc LLC and others for $49 million in a reverse merger transaction.	23-01-16	CI
Angion Biomedica Gets Non-Compliance Notice From Nasdaq	22-12-22	MT
Angion Biomedica Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Angion Biomedica Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Earnings Flash (ANGN) ANGION BIOMEDICA Posts Q2 Revenue $653,000	22-08-15	MT
Earnings Flash (ANGN) ANGION BIOMEDICA Posts Q2 Loss $-0.30	22-08-15	MT
Angion Announces Process to Explore Strategic Alternatives for Enhancing and Preserving Shareholder Value	22-07-25	CI
Angion Biomedica Corp. Announces Resignation of John F. Neylan as Chief Medical Officer and Head of Research, Effective on August 15, 2022	22-07-25	CI
Angion Biomedica to Explore Strategic Alternatives to Boost Shareholder Value	22-07-25	MT
HC Wainwright Downgrades Angion Biomedica to Neutral From Buy	22-07-18	MT
Sector Update: Health Care Stocks Swoon Late, Closing Lower	22-06-30	MT
Top Midday Decliners	22-06-30	MT
Sector Update: Health Care Stocks Little Changed on Thursday	22-06-30	MT
Sector Update: Health Care	22-06-30	MT

Chart ANGN BIOM

Duration

Period

More charts

Company Profile

Angion Biomedica Corp. is a clinical-stage company. The Company is focused on the discovery, development, and commercialization of novel small molecule therapeutics to address chronic and progressive fibrotic diseases. The Company's product candidates and programs include ANG-3070, a highly selective oral tyrosine kinase receptor inhibitor (TKI) in development as a treatment for fibrotic diseases, a ROCK2 preclinical program targeted towards the treatment of fibrotic diseases, a CYP11B2 preclinical program targeted towards diseases related to aldosterone synthase dysregulation, and a CYP26 (retinoic acid metabolism) inhibitor program targeted towards a number of biopharmaceutical indications, including cancer, and ANG-3777, a hepatocyte growth factor (HGF) mimetic. Its ROCK2 program includes a number of highly selective, oral small molecule inhibitors of ROCK2 developed internally as a potential treatment for fibrotic and other diseases.

Sector

More about the company

Income Statement Evolution

More financial data